Evaluate the significance of restoring domestic Penicillin G production for India's health security.

Penicillin G is the fermentation-based Key Starting Material from which 6-APA, amoxicillin and ampicillin are derived — the backbone of Indian primary-care antibiotics. Its domestic manufacture, restored at Kakinada after nearly three decades under the PLI Scheme for Bulk Drugs, is a genuine gain for health security, though its durability remains unproven.

Significance for health security

• Ends a concentrated strategic vulnerability: about two-thirds of India's bulk drug and intermediate imports come from China [4]; a single export curb or port disruption could halt the entire β-lactam antibiotic chain.
• Backward integration: Lyfius Pharma's 15,000 MT per annum plant reports over 90% domestic value addition, converting India from a formulator dependent on imported inputs into a maker of the molecule itself [1].
• Demonstrated import substitution: Sulfadiazine imports fell about 73% against the FY2019-20 baseline, and India's first fermentation-based Potassium Clavulanate plant at Nalagarh now supplies the β-lactamase inhibitor paired with amoxicillin [1].
• Wider gains: 2,353 direct jobs at Kakinada alone, plus capacity spread across Andhra Pradesh, Himachal Pradesh, Gujarat and Punjab [1].

Limits of the achievement

• The cost gap persists: Chinese APIs remain roughly 35-40% cheaper [4], so formulators may still import despite domestic capacity.
• Incentive is time-bound, disadvantage is not: PLI pays against production for a fixed term; once it lapses, plants face the same power and effluent costs that killed Penicillin G earlier [1].
• Scale is modest: by December 2025, 38 of 48 approved projects were commissioned and avoided imports stood at ₹2,192 crore against a ₹6,940 crore outlay [5][2] — capacity created, dependence not ended.

Restoring Penicillin G is best evaluated as strategic insurance: it restores the option to manufacture, which is decisive in a crisis. Converting that option into competitive supply requires the Katoch Committee's design — bulk drug parks with common effluent treatment, assured power and shared utilities under an SPV [7] — supported by preferential public procurement of high value-addition APIs, so that self-reliance outlives the incentive.